ALYMSYS vs LUMAKRAS

Independent side-by-side comparison.

Rated against independent regulatory sources·Last updated August 21, 2026·How we rate

Possible drug interaction. ALYMSYS and LUMAKRAS are different prescription medicines. Combining or switching between them can cause interactions — talk to a pharmacist or prescriber before making changes. This page is not medical advice.

Attribute	ALYMSYS	LUMAKRAS
Rating	70/100	72/100
Pharmacy pays	—	—
Type	RX	RX
Active ingredient	BEVACIZUMAB-MALY	SOTORASIB
Manufacturer	Amneal	Amgen Inc
Dosage forms	Injectable	Tablet
Drug class	—	—
Boxed warning	None	None
Treats	Non-Small-Cell Lung Carcinoma, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms	Non-Small-Cell Lung Carcinoma

alymsys lumakras

Rating

70/100

72/100

Pharmacy pays

—

Type

Active ingredient

BEVACIZUMAB-MALY

SOTORASIB

Manufacturer

Amneal

Amgen Inc

Dosage forms

Injectable

Tablet

Drug class

—

Boxed warning

None

Treats

Non-Small-Cell Lung Carcinoma, Uterine Cervical Neoplasms, Fallopian Tube Neoplasms

Non-Small-Cell Lung Carcinoma

Frequently asked questions

Which is better-rated, Alymsys or Lumakras?

By our independent rating, Lumakras scores higher — 3.6 vs 3.5 out of 5 for Alymsys. Ratings are based on FDA regulatory (recall-safety) data.

What is the difference between Alymsys and Lumakras?

Alymsys contains Bevacizumab-Maly, while Lumakras contains Sotorasib — they have different active ingredients.

Ratings are based on FDA regulatory (recall-safety) data. This comparison is for general reference only — not medical advice. Always consult a licensed professional before choosing or switching a medication.